Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06814717 · ClinicalTrials.gov registry record · Phase 2
A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns
A Phase 2 study of Thermal Burns, sponsored by Neomatrix Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT06814717: Recruiting Phase 2 study of Thermal Burns, sponsored by Neomatrix Therapeutics.
NCT06814717 is a Phase 2 study of Thermal Burns that is actively recruiting participants, run by Neomatrix Therapeutics. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06814717, a Phase 2 study of Thermal Burns, is actively recruiting participants, sponsored by Neomatrix Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2a, open-label, single-dose study to evaluate the safety, tolerability, and PK profile of cP12 in 6 male and female subjects with thermal burns of up to and including 10% TBSA. Enrolled subjects must have at least 1% superficial (epidermal), superficial partial-thickness, or deep partial-thickness burns. Eligible subjects will receive a single administration of 0.01 mg/kg cP12. Vital signs, ECGs, and blood samples and urine samples will be obtained at screening and at several time points during the study for safety evaluation. Burn and pain assessments will be completed at specified times. Subjects will remain at the clinical site for at least 6 hours post infusion for the purpose of safety monitoring and evaluation of other study assessments. Subsequent evaluations will be performed at the clinical site 3 (±1) days and 7 (±2) days after dosing. Subjects will return to the clinical site 14 (±2) days after dosing for an End-of-Study visit.
Primary Outcome
Clinical safety labs will be collected
Conditions Studied
Interventions
- DRUG cP12
Study Locations (1)
District of Columbia
- Medstar Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2026-11-01 |
| Phase | Phase 2 |
What NCT06814717 shows while recruiting
NCT06814717 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Thermal Burns appearing as the primary indexed condition, and to 1 intervention - of which cP12 is the first listed.
NCT06814717 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT06814717 about?
NCT06814717 is a clinical study titled "A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns". This is a Phase 2a, open-label, single-dose study to evaluate the safety, tolerability, and PK profile of cP12 in 6 male and female subjects with thermal burns of up to and including 10% TBSA. Enrolled subjects must have at least 1% superficial (epidermal), superficial partial-thickness, or deep par...
What is the current status of trial NCT06814717?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2025-05-12. Estimated completion is 2026-11-01.
What conditions does trial NCT06814717 study?
This clinical trial studies the following conditions: Thermal Burns.
What interventions are being tested in trial NCT06814717?
The interventions under investigation include: cP12 (DRUG).
Who is sponsoring clinical trial NCT06814717?
This trial is sponsored by Neomatrix Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06814717 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thermal Burns
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06814717's enrollment target sits among peer trials
6 1997th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI